Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in
young children and elderly people. Although the virus was isolated in 1955, an effective …

The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the
attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of …

Human respiratory syncytial virus (RSV) is a ubiquitous pathogen that infects everyone
worldwide early in life and is a leading cause of severe lower respiratory tract disease in the …

Respiratory syncytial virus (RSV) invades host cells via a type I fusion (F) glycoprotein that
undergoes dramatic structural rearrangements during the fusion process. Neutralizing …

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in
young children and the elderly. Therapeutic small molecules have been developed that bind …

Recombinant proteins are important therapeutics due to potent, highly specific, and nontoxic
actions in vivo. However, they are expensive medicines to manufacture, chemically …

GS-5806 is a novel, orally bioavailable RSV fusion inhibitor discovered following a lead
optimization campaign on a screening hit. The oral absorption properties were optimized by …

The development of antiviral strategies to prevent or treat respiratory syncytial virus (RSV)
infections is of great importance, especially considering the fact that RSV is one of the most …

Infection of cells by enveloped viruses requires merger of the viral envelope membrane with
target cell membranes, resulting in the formation of fusion pores through which the viral …

Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young
children, immunocompromised adults, and the elderly. Intervention with small-molecule …